AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces
Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
AbbVie Falters Despite Progress in Lymphoma Treatment
AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Narus Financial Partners LLC Has $476,000 Stock Position in AbbVie Inc. (NYSE:ABBV)
Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...
BMO Capital Markets Boosts AbbVie (NYSE:ABBV) Price Target to $220.00
AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...
12 Analysts Have This To Say About Genmab
Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...